Published in Drug Week, November 25th, 2011
"To address this, our study uses alpha-synuclein transgenic mice, expressing human alpha-synuclein or alpha-synuclein-eGFP under the (h) PDGF-beta promoter, in combination with in vivo pharmacologic and multiphoton imaging strategies to systematically test degradation pathways in the living mouse...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.